Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $19 to $14.
Stocks · News reference
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $24 to $21.
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11
Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weight and lowers the price target from $15 to $11.
Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12
Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the price target from $11 to $12.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.